English (United Kingdom)   French (Fr)
Équipe Paul HOFMAN

Presentation

Equipe de Recherche Fondamentale  3  « Inflammation et Carcinogenèse »

Pr Paul HOFMAN, PU-PH, Chef d'Equipe


Résumé


Increasing evidence supports the involvement of systemic inflammation in cancer development and progression (Mantovani et al., 2008). Apart from their well-established function as effector cells against invading pathogens, it is certain that neutrophils are involved in carcinogenesis (Hofman, 2010). Our current work focus on non-small cell lung cancers, because of the lack of predictive biomarkers and therapeutic targets. Moreover, for this cancer, metastatic diseases remain the foremost cause of cancer-related death.

Our project is divided into the following objectives:

i/ To characterize the role of the microenvironment on PMNL maturation (aims 1-2),

ii/ To decipher the involvement of PMNL and miRNA transfer in epithelial cell transformation (aims 2-3), and iii/ in tumour progression and dissemination (aim 4).

From a basic research point of view — Implementation of this project will help to define not only the sequence of events occurring from chronic inflammation to cancer onset, but also the specific fingerprint of PMNL recruited at sites of inflammation and/or within the tumour microenvironment.

Both in vitro, in vivo and ex vivo strategies will be used to accomplish our goal. We have already developed cellular and mouse models of colonic and lung cancer that allow us to test our approaches prior to clinical translation. Such an integrative strategy is expected to lead to much greater accuracy and cost-effectiveness than either strategy alone. Three scientists (two CR1 INSERM and one CR1 CNRS) together with post-doctoral fellows and doctoral students with a broad range of expertise in animal models, PMNL biology, miRNA/genotype and analysis of autophagy will dedicate 100 % of their time for this project.


The bench-to-bedside translation will be accomplished through the integration of the clinical translation core (7 physicians: three surgical pathologists, one pneumologist, one gastroenterologist, two surgeons, all of them strongly involved in translational and clinical research).


Taken together, we will answer the important question of how neutrophil/cancer cell crosstalk may impact on tumourigenesis and tumour progression and dissemination. Not only will our study bring fundamental knowledge but will also lead to the identification of new potential biomarkers and therapeutic targets of significant interest to the field of oncology.

Projet de Recherche

Projet de Recherche


Role of neutrophil-rich microenvironment in carcinogenesis onset and carcinoma progression


Several epidemiological and histological data highlight that intense and repeated neutrophil infiltration for a long period time is strongly linked with a high risk of carcinoma onset. However, eventhough different mechanisms were claimed to explain onset of carcinogenesis in response to repeated neutrophil transepithelial migration and/or neutrophil epithelial contact, the pathophysiological of this process is complex and its understanding is limited to date. Within a tumour, the cancer cells are surrounded by an inflammatory microenvironment containing different cell’s subtypes. Accumulating evidence highly suggests that cancer cells attract inflammatory cells, in particular polymorphonuclear leukocytes (PMNL, ie neutrophils) and might subvert their functions to promote tumour cell proliferation, resistance again cell death and metastasis. However, the relationship between cytokines, epithelial cells and PMNL, and the consequence of such cell-cell interaction on regulation of downstream events (such as miRNA regulation and/or protein expression), has been poorly investigated, in particular during the critical transition from a chronic “active” inflammatory lesion to a carcinoma.


Our project is divided in three main objectives : i) to characterize the role of microenvironment in PMNL maturation (aim 1), ii) to characterize PMNL involvement in tumor initiation (aim 2) and in tumor progression and dissemination (aim 3)


To conduct this project, we will use an integrative strategy which combined in vitro, in vivo and ex vivo studies. Our molecular and cellular approaches will be facilitated by different state-of-art facilities available in our pathology laboratory and our human biobank (www.biobank06.com).


From a basic research point of view — Implementation of this project will help to define not only the sequence of events occurring from a chronic inflammation to a cancer onset but also the specific fingerprints of PMNL recruited at site of inflammation or at tumour microenvironment.


From a clinical research point of view — Most of the current chemotherapies directly kill cancer cells; a strategy that however meets rapid drug resistance in large part due to the inherent genomic instability of cancer cells. We propose that tumour-associated PMNL (TANs), which are highly concentrated in tumour microenvironment, are promising biomarkers and potential targets for new drug development.


The broad translational potential of this project resides in its ability to provide validated targets for :

1)    Assessing the genetic susceptibility of individuals to develop cancer,

2)    Development of early prognostic biomarkers for management of cancer patients.

3)  New therapeutic strategies aimed at limiting inflammation (PMNL recruitment), cancer growth or metastasis (reprogramming PMNL cytotoxic activity).


Aim 1 : Control of neutrophils maturation : Potential role of microenvironment


Strikingly, we frequently observe within human carcinomas, such as lung carcinoma, that intratumoral PMNL can be tightly associated with tumoral cells in areas without necrosis, but also around large areas of necrosis. This observation raises the following question: are there two populations of tumour-associated PMNL (TANs), one cytotoxic associated with dead tumor cells and one pro-tumoral in close proximity with alived tumor cells ?


In agreement with this proposal, Friedlander et al described in a mice model of lung cancer two TANs populations that are drived by TGFb signalling (Fridlender et al., 2009). Our general aim is to characterize the difference in PMNL subpopulation present respectively in a non tumoural and in a tumoural microenvironment.


Results based on tumoral microenvironment dependent subversion of PMNL functions will enable us to propose new mechanisms and biomarkers of tumour initiation.


Aim 2 : Role of PMNL in tumour initiation


Recent genome wide association projects highlighted single nucleotide polymorphisms (SNP) as cancer susceptibility genes in the general population (Stacey et al., 2009). However, most of these SNP are silent and therefore their pathological consequences were not studied to date. We recently demonstrated that an inflammatory environment reveals SNP’s pathological consequences via disturbing miRNA-mRNA binding (Brest et al., 2010b).


Interestingly numerous genetic variations are present on genes involved genome stability. We therefore will focus our attention on cancer-associated SNP that could affect genome stability. The core of our proposal lies on the hypothesis that even minute decrease in DNA stability/repair may significantly increase the risk of developing cancer over lifetime, particularly in response to PMNL-rich microenvironment.


Our general aim is to investigate if a PMNL rich-microenvironment might promote cancer development by disturbing genome stability.

We believe that results of this study that may support a role for SNP/miRNA regulation of telomerase and telomere stability will enable us to improve individualized risk prognosis and could assist in the development of personalized new therapeutic strategies.


Aim 3 : Role of TANs in circulating tumor cells dissemination


Metastasis is the leading cause of death in cancer patients. This is likely because the mechanisms behind tumour dissemination, through circulating tumor cells  (CTC) present in the blood stream are not fully understood

Using a state-of-art platform for detecting CTC by using both indirect and direct approaches, we recently proposed CTCs as valuable index of the risk for developing metastases in lung carcinoma (Hofman et al., 2010a; Hofman et al., 2010b). Moreover, we made the original observation that PMNL frequently stick to CTC clumps which raises the question: are CTC co-migrate with PMNL ?


Our general goal is to study CTC biology, particularly their dialogue with TANs

We believe that results of this study will enable us to assist in the development of early biomarkers of tumor dissemination.


RELEVANCE FOR DIAGNOSTIC, PRONOSTIC AND THERANOSTIC

The achievement of this program benefits of

the range of expertises possessed by the applicant team;

* the insertion of our team within the INSERM Biobank and Laboratory of Clinical and Experimental Pathology (www.biobank06.com) ;

the development of different in vitro, in vivo and ex vivo tools; and

national and international collaborations

Such unique synergy should greatly speed up the translation of our findings into the clinical practice.


Equipe de Recherche

Equipe de Recherche


HOFMAN Paul, PU-PH, Team Leader
Tel. +33 (0)4 92 03 88 55, +33 (0)4 92 03 16 02
Mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it


BORDONE Olivier, AI UNS
Tel. +33 (0)4 93 37 70 32, Mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it

BOZEC Alexandre, PH
Tel. +33 (0)4 93 37 70 32, Mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it

BREST Patrick, CR1 INSERM
Tel. +33 (0)4 92 03 12 45, Mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it

GOLDONI, Dana, Post-Doc
Tel. +33 (0)4 92 03 12 45, Mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it

HEBUTERNE Xavier, PU-PH
Tel. +33 (0)4 92 03 12 45, Mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it

HOFMAN Véronique, PH
Tel. +33 (0)4 92 03 88 55, Mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it

ILIE Marius, PhD Student
Tel. +33 (0)4 92 03 88 55, Mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it

JUHEL Thierry, TE INSERM
Tel. +33 (0)4 92 03 12 42, Mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it

MARQUETTE Charles-Hugo, PU-PH
Tel. +33 (0)4 92 03 12 45, Mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it

MIMOUNA Sanda, PhD Student
Tel. +33 (0)4 92 03 16 00, Mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it

MOGRABI Baharia, CR1 INSERM
Tel. +33 (0)4 92 03 12 45, Mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it

MOUROUX Jérôme, PU-PH
Tel. +33 (0)4 93 37 70 32, Mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it

MUSSO-LASSALE Sandra, MCU-PH
Tel. +33 (0)4 92 03 88 55, Mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it

VOURET-CRAVIARI Valérie, CR1 CNRS
Tel. +33 (0)4 92 03 12 23, Mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it

ZANGARI Joséphine, AI
Tel. +33 (0)4 92 03 16 00, Mail : This e-mail address is being protected from spambots. You need JavaScript enabled to view it  

Brevets

Brevets

Based on our research results, we have filed 6 International/European patents or patent applications with INSERM Transfer.


2010 : Patrick Brest, B. Mograbi, P. Hofman :
« Method for diagnosing and treating a pathology using genetic score based on risk associated allele combination »
Brevet européen en cours de dépôt par INSERM transfert, 2010.

2009 : Patrick Brest, B. Mograbi, P. Hofman :
« Method for determining the efficiency of a cancer treatment »
Brevet européen N° EP BIO 09243 déposé par INSERM transfert, 2009.

2009 : Patrick Brest, B. Mograbi, P. Hofman :
« Method for diagnosing and treating a pathology associated with a synonymous mutation occurring within a gene of interest »
Brevet européen N° EP BIO 09284 déposé par INSERM transfert, 2009.

2009 : A. Darfeuille-Michaud, Paul Hofman, N. Rolhion :
« Antagonist of the prevention or treatment of inflammatory bowel disease and more particularly of Crohn’s disease »
Brevet européen, 2009.

Publications

Publications


http://www.ncbi.nlm.nih.gov/pubmed/?term=paul+hofman


In the past four years, all team investigators have published their results in 110 peer reviewed journals, many of which appear in journals with a high impact factor. These include Nature Genetics (2 articles), New England Journal of Medicine (1 article), Lancet (2 articles), JAMA (1 article), Cancer Research (4 articles), British Journal of Cancer (6 articles), International Journal of Cancer (5 articles), Cancer Cell (1 article), Gut (1 article), Gastroenterology (2 articles), Autophagy (2 articles), PLoS Group (3 articles), Cellular Microbiology (1 article), Endocrine-realted cancer (2 papers), Current Medicinal Chemistry (4 articles), Current Molecular Medicine (1 article) and Current Opinion in Oncology (1 article).


Based on our research results, we have filed 6 International/European patents or patent applications with INSERM Transfer.


50 selected publications (2009-2013)



Korzeniewski S, Hofman P, Brest P. Noisy silent polymorphisms. Med Sci (Paris). 2013 Feb;29(2):124-6.


Ilie MI, Lassalle S, Long-Mira E, Hofman V, Zangari J, Bénaim G, Bozec A, Guevara N, Haudebourg J, Birtwisle-Peyrottes I, Santini J, Brest P, Hofman P. In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF (V600E)mutation status and together with hypoxia-related proteins predicts aggressive behavior. Virchows Arch. 2013 Sep;463(3):437-44.


Belaid A, Cerezo M, Chargui A, Corcelle-Termeau E, Pedeutour F, Giuliano S,Ilie M, Rubera I, Tauc M, Barale S, Bertolotto C, Brest P, Vouret-Craviari V, Klionsky DJ, Carle GF, Hofman P, Mograbi B. Autophagy plays a critical role in the degradation of active RHOA, the control of cell cytokinesis, and genomic stability. Cancer Res. 2013 Jul 15;73(14):4311-22.


Ilie M, Hofman V, Zangari J, Chiche J, Mouroux J, Mazure NM, Pouysségur J,Brest P, Hofman P. Response of CAIX and CAXII to in vitro re-oxygenation and clinical significance of the combined expression in NSCLC patients. Lung Cancer. 2013 Oct;82(1):16-23.


Gensollen T, Bourges C, Rihet P, Rostan A, Millet V, Noguchi T, Bourdon V, Sobol H, Dubuquoy L, Bertin B, Fumery M, Desreumaux P, Colombel JF, Hebuterne X, Hofman P, Naquet P, Galland F. Functional polymorphisms in the regulatory regions of the VNN1 gene are associated with susceptibility to inflammatory bowel diseases. Inflamm Bowel Dis. 2013 Oct;19(11):2315-25.


Belaid A, Ndiaye PD, Klionsky DJ, Hofman P, Mograbi B. Signalphagy: Scheduled signal termination by macroautophagy. Autophagy. 2013 Aug 13;9(10).


Belaid A, Ndiaye PD, Cerezo M, Cailleteau L, Brest P, Klionsky DJ, Carle GF, Hofman P, Mograbi B. Autophagy and SQSTM1 on the RHOA(d) again: Emerging roles of autophagy in the degradation of signaling proteins. Autophagy. 2013 Nov 26;10(2).


Vincent-Bugnas S, Vitale S, Mouline CC, Khaali W, Charbit Y, Mahler P, Prêcheur I, Hofman P, Maryanski JL, Doglio A. EBV Infection Is Common in Gingival Epithelial Cells of the Periodontium and Worsens during Chronic Periodontitis. PLoS One. 2013 Dec 19;8(12):e80336.


Hofman V, Ilie M, Long-Mira E, Giacchero D, Butori C, Dadone B, Selva E, Tanga V, Passeron T, Poissonnet G, Emile JF, Lacour JP, Bahadoran P, Hofman P. Usefulness of Immunocytochemistry for the Detection of the BRAF(V600E) Mutation in Circulating Tumor Cells from Metastatic Melanoma Patients. J Invest Dermatol. 2013 Jan 10.


Sanfiorenzo C, Ilie MI, Belaid A, Barlési F, Mouroux J, Marquette CH, Brest P, Hofman P. Two Panels of Plasma MicroRNAs as Non-Invasive Biomarkers for Prediction of Recurrence in Resectable NSCLC.  PLoS One. 2013;8(1):e54596.

Chargui A., Cesaro A., Mimouna S., Fareh M., Brest P., Naquet Ph., Darfeuille-Michaud A., Hébuterne X., Mograbi B., Vouret-Craviari, Hofman P.  Subversion of autophagy in adherent invasive escherichia coli-infected neutrophils induces inflammation and cell death. PLOS ONE, Dec 2012, 7, 12, e 51727.


Ilie M, Hofman V, Ortholan C, Bonnetaud C, Coelle C, Mouroux J, Hofman P. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer 2012;118:1726-37.


Ilie M, Hofman P. Pitfalls in Lung Cancer Molecular Pathology: How to Limit them in Routine Practice ? Curr Med Chem 2012;19:2638-51.


Hofman V, Long E, Ilie M, Bonnetaud C, Vignaud JM, Flejou JF, Lantuejoul S, Piaton E, Mourad N, Butori C, Selva E, Marquette CH, Poudenx M, Sibon S, Kelhef S, Venissac N, Jais JP, Mouroux J, Molina TJ, Vielh P, Hofman P. Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method. Cytopathology 2012;23:30-8.


Hofman V, Gaziello MC, Bonnetaud C, Ilie M, Mauro V, Long E, Selva E, Gavric-Tanga V, Lassalle S, Butori C, Papin-Michaud C, Lerda N, Bordone O, Coelle C, Sabourin JC, Chabannon C, Hofman P. [Setting up indicators in biobanking: why and how ?]. Ann Pathol 2012;32:91-101.


Hofman P, Vouret-Craviari V. Microbes-induced EMT at the crossroad of inflammation and cancer. Gut Microbes 2012;3.


Giovannini-Chami L, Marcet B, Moreilhon C, Chevalier B, Illie MI, Lebrigand K, Robbe-Sermesant K, Bourrier T, Michiels JF, Mari B, Crenesse D, Hofman P, de Blic J, Castillo L, Albertini M, Barbry P. Distinct epithelial gene expression phenotypes in childhood respiratory allergy. Eur Respir J 2012;39:1197-205.


Doyen J, Alix-Panabieres C, Hofman P, Parks SK, Chamorey E, Naman H, Hannoun-Levi JM. Circulating tumor cells in prostate cancer: a potential surrogate marker of survival. Crit Rev Oncol Hematol 2012;81:241-56.


Darini CY, Pisani DF, Hofman P, Pedeutour F, Sudaka I, Chomienne C, Dani C, Ladoux A. Self-renewal gene tracking to identify tumour-initiating cells associated with metastatic potential. Oncogene 2012;31:2438-49.


Cheli Y, Giuliano S, Fenouille N, Allegra M, Hofman V, Hofman P, Bahadoran P, Lacour JP, Tartare-Deckert S, Bertolotto C, Ballotti R. Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells. Oncogene 2012;31:2461-70.


Brahimi-Horn MC, Ben-Hail D, Ilie M, Gounon P, Rouleau M, Hofman V, Doyen J, Mari B, Shoshan-Barmatz V, Hofman P, Pouyssegur J, Mazure NM. Expression of a truncated active form of VDAC1 in lung cancer associates with hypoxic cell survival and correlates with progression to chemotherapy resistance. Cancer Res 2012;72:2140-50.


Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, Zangari J, Bille K, Robert C, Bressac-de Paillerets B, Hofman P, Rocchi S, Peyron JF, Lacour JP, Ballotti R, Bertolotto C. Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev 2011;25:1245-61.


Mimouna S, Goncalves D, Barnich N, Darfeuille-Michaud A, Hofman P, Vouret-Craviari V. Crohn disease-associated Escherichia coli promote gastrointestinal inflammatory disorders by activation of HIF-dependent responses. Gut Microbes 2011;2.


Lassalle S, Hofman V, Ilie M, Bonnetaud C, Puissegur MP, Brest P, Loubatier C, Guevara N, Bordone O, Cardinaud B, Lebrigand K, Rios G, Santini J, Franc B, Mari B, Al Ghuzlan A, Vielh P, Barbry P, Hofman P. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland? Endocr Relat Cancer 2011;18:579-94.


Ilie MI, Hofman V, Ortholan C, Ammadi RE, Bonnetaud C, Havet K, Venissac N, Mouroux J, Mazure NM, Pouyssegur J, Hofman P. Overexpression of carbonic anhydrase XII in tissues from resectable non-small cell lung cancers is a biomarker of good prognosis. Int J Cancer 2011;128:1614-23.


Hofman VJ, Ilie MI, Bonnetaud C, Selva E, Long E, Molina T, Vignaud JM, Flejou JF, Lantuejoul S, Piaton E, Butori C, Mourad N, Poudenx M, Bahadoran P, Sibon S, Guevara N, Santini J, Venissac N, Mouroux J, Vielh P, Hofman PM. Cytopathologic detection of circulating tumor cells using the isolation by size of epithelial tumor cell method: promises and pitfalls. Am J Clin Pathol 2011;135:146-56.


Hofman V, Ilie MI, Long E, Selva E, Bonnetaud C, Molina T, Venissac N, Mouroux J, Vielh P, Hofman P. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay and the isolation by size of epithelial tumor cell method. Int J Cancer 2011;129:1651-60.


Hofman V, Bonnetaud C, Ilie MI, Vielh P, Vignaud JM, Flejou JF, Lantuejoul S, Piaton E, Mourad N, Butori C, Selva E, Poudenx M, Sibon S, Kelhef S, Venissac N, Jais JP, Mouroux J, Molina TJ, Hofman P. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res 2011;17:827-35.


Hofman P, Ilie M, Hofman V, Roux S, Valent A, Bernheim A, Alifano M, Leroy-Ladurie F, Vaylet F, Rouquette I, Validire P, Beau-Faller M, Lacroix L, Soria JC, Fouret P. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol 2011.


Cheli Y, Giuliano S, Botton T, Rocchi S, Hofman V, Hofman P, Bahadoran P, Bertolotto C, Ballotti R. Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 2011;30:2307-18.


Cambon-Thomsen A, Thorisson GA, Mabile L, Andrieu S, Bertier G, Boeckhout M, Carpenter J, Dagher G, Dalgleish R, Deschenes M, di Donato JH, Filocamo M, Goldberg M, Hewitt R, Hofman P, Kauffmann F, Leitsalu L, Lomba I, Melegh B, Metspalu A, Miranda L, Napolitani F, Oestergaard MZ, Parodi B, Pasterk M, Reiche A, Rial-Sebbag E, Rivalle G, Rochaix P, Susbielle G, Tarasova L, Thomsen M, Zawati MH, Zins M. The role of a Bioresource Research Impact Factor as an incentive to share human bioresources. Nat Genet 2011;43:503-4.


Brest P, Lassalle S, Hofman V, Bordone O, Gavric Tanga V, Bonnetaud C, Moreilhon C, Rios G, Santini J, Barbry P, Svanborg C, Mograbi B, Mari B, Hofman P. MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. Endocr Relat Cancer 2011;18:711-9.


Brest P, Lapaquette P, Souidi M, Lebrigand K, Cesaro A, Vouret-Craviari V, Mari B, Barbry P, Mosnier JF, Hebuterne X, Harel-Bellan A, Mograbi B, Darfeuille-Michaud A, Hofman P. A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat Genet 2011;43:242-5.


Brest P, Lapaquette P, Mograbi B, Darfeuille-Michaud A, Hofman P. Risk predisposition for Crohn disease: a "menage a trois" combining IRGM allele, miRNA and xenophagy. Autophagy 2011;7:786-7.


Braz-Silva PH, Vitale S, Butori C, Guevara N, Santini J, Magalhaes M, Hofman P, Doglio A. Specific infiltration of langerin-positive dendritic cells in EBV-infected tonsil, Hodgkin lymphoma and nasopharyngeal carcinoma. Int J Cancer 2011;128:2501-8.


Bozec A, Dassonville O, Chamorey E, Poissonnet G, Sudaka A, Peyrottes I, Ettore F, Haudebourg J, Bussiere F, Benisvy D, Marcy PY, Sadoul JL, Hofman P, Lassale S, Vallicioni J, Demard F, Santini J. Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases. Eur Arch Otorhinolaryngol 2011;268:1205-12.


Mari M, Hofman V, Butori C, Ilie M, Lassalle S, Grier P, Sadoulet D, Scoazec JY, Hofman P. What is new in 2010 for electron microscopy in surgical pathology ?. Ann Pathol 2010;30:263-72.


Lassalle S, Hofman V, Ilie M, Butori C, Bozec A, Santini J, Vielh P, Hofman P. Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications. Curr Med Chem 2010;17:1839-50.


Ilie MI, Hofman V, Bonnetaud C, Havet K, Lespinet-Fabre V, Coelle C, Gavric-Tanga V, Venissac N, Mouroux J, Hofman P. Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Arch 2010;457:483-95.


Ilie M, Mazure NM, Hofman V, Ammadi RE, Ortholan C, Bonnetaud C, Havet K, Venissac N, Mograbi B, Mouroux J, Pouyssegur J, Hofman P. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer 2010;102:1627-35.


Ilie M, Hofman V, Pedeutour F, Attias R, Santini J, Hofman P. Oncocytic lipoadenoma of the parotid gland: Immunohistochemical and cytogenetic analysis. Pathol Res Pract 2010;206:66-72.


Ilie M, Guevara N, Castillo L, Hofman P. Polypoid intranasal mass caused by Rosai-Dorfman disease: a diagnostic pitfall. J Laryngol Otol 2010;124:345-8.


Hofman V, Ilie M, Gavric-Tanga V, Lespinet V, Mari M, Lassalle S, Butori C, Coelle C, Bordone O, Selva E, Lamy A, Sabourin JC, Hofman P. [Role of the surgical pathology laboratory in the pre-analytical approach of molecular biology techniques]. Ann Pathol 2010;30:85-93.


Hofman V, Dhouibi A, Butori C, Padovani B, Gari-Toussaint M, Garcia-Hermoso D, Baumann M, Venissac N, Cathomas G, Hofman P. Usefulness of molecular biology performed with formaldehyde-fixed paraffin embedded tissue for the diagnosis of combined pulmonary invasive mucormycosis and aspergillosis in an immunocompromised patient. Diagn Pathol 2010;5:1.


Hofman V, Bonnetaud C, Gaziello MC, Ilie M, Lassalle S, Butori C, Lerda N, Selva E, Gavric-Tanga V, Castillo L, Guevara N, Santini J, Pop D, Venissac N, Mouroux J, Chabannon C, Hofman P. [The Nice CHU biobank experience to collect patients' informed consent for research context (2004-2009)]. Ann Pathol 2010;30:337-43.


Giuliano S, Cheli Y, Ohanna M, Bonet C, Beuret L, Bille K, Loubat A, Hofman V, Hofman P, Ponzio G, Bahadoran P, Ballotti R, Bertolotto C. Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas. Cancer Res 2010;70:3813-22.


Cesaro A, Brest P, Hofman V, Hebuterne X, Wildman S, Ferrua B, Marchetti S, Doglio A, Vouret-Craviari V, Galland F, Naquet P, Mograbi B, Unwin R, Hofman P. Amplification loop of the inflammatory process is induced by P2X7R activation in intestinal epithelial cells in response to neutrophil transepithelial migration. Am J Physiol Gastrointest Liver Physiol 2010;299:G32-42.


Cane G, Ginouves A, Marchetti S, Busca R, Pouyssegur J, Berra E, Hofman P, Vouret-Craviari V. HIF-1alpha mediates the induction of IL-8 and VEGF expression on infection with Afa/Dr diffusely adhering E. coli and promotes EMT-like behaviour. Cell Microbiol 2010;12:640-53.


Brest P, Corcelle EA, Cesaro A, Chargui A, Belaid A, Klionsky DJ, Vouret-Craviari V, Hebuterne X, Hofman P, Mograbi B. Autophagy and Crohn's disease: at the crossroads of infection, inflammation, immunity, and cancer. Curr Mol Med 2010;10:486-502.


Braz-Silva PH, Magalhaes MH, Hofman V, Ortega KL, Ilie MI, Odin G, Vielh P, Hofman P. Usefulness of oral cytopathology in the diagnosis of infectious diseases. Cytopathology 2010;21:285-99.


Bozec A, Lassalle S, Hofman V, Ilie M, Santini J, Hofman P. The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem 2010;17:3449-61.

Thariat J, Hamoir M, Janot F, De Mones E, Marcy PY, Carrier P, Bozec A, Guevara N, Albert S, Vedrine PO, Graff P, Peyrade F, Hofman P, Santini J, Bourhis J, Lapeyre M. [Neck dissection following chemoradiation for node positive head and neck carcinomas]. Cancer Radiother 2009;13:758-70.


Robert G, Ben Sahra I, Puissant A, Colosetti P, Belhacene N, Gounon P, Hofman P, Bost F, Cassuto JP, Auberger P. Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death. PLoS One 2009;4:e7889.


Ortholan C, Puissegur MP, Ilie M, Barbry P, Mari B, Hofman P. MicroRNAs and lung cancer: new oncogenes and tumor suppressors, new prognostic factors and potential therapeutic targets. Curr Med Chem 2009;16:1047-61.


Marchetti S, Gamas P, Belhacene N, Grosso S, Pradelli LA, Colosetti P, Johansen C, Iversen L, Deckert M, Luciano F, Hofman P, Ortonne N, Khemis A, Mari B, Ortonne JP, Ricci JE, Auberger P. The caspase-cleaved form of LYN mediates a psoriasis-like inflammatory syndrome in mice. EMBO J 2009;28:2449-60.


Long E, Ilie M, Hofman V, Havet K, Selva E, Butori C, Lacour JP, Nelson AM, Cathomas G, Hofman P. LANA-1, Bcl-2, Mcl-1 and HIF-1alpha protein expression in HIV-associated Kaposi sarcoma. Virchows Arch 2009;455:159-70.


Lassalle S, Hofman V, Marius I, Gavric-Tanga V, Brest P, Havet K, Butori C, Selva E, Santini J, Mograbi B, Hofman P. Assessment of morphology, antigenicity, and nucleic acid integrity for diagnostic thyroid pathology using formalin substitute fixatives. Thyroid 2009;19:1239-48.


Italiano A, Cortot AB, Ilie M, Martel-Planche G, Fabas T, Pop D, Mouroux J, Hofman V, Hofman P, Pedeutour F. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer 2009;125:2479-82.


Ilie M, Hofman V, Butori C, Lassalle S, Hofman P. [Pathologic findings and main aetiologies of rhinosinusal infections]. Ann Pathol 2009;29:313-22.


Hofman V, Lassalle S, Bonnetaud C, Butori C, Loubatier C, Ilie M, Bordone O, Brest P, Guevara N, Santini J, Franc B, Hofman P. Thyroid tumours of uncertain malignant potential: frequency and diagnostic reproducibility. Virchows Arch 2009;455:21-33.

Financements

Financements